S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83

Zogenix Stock Forecast, Price & News

+0.49 (+3.95%)
(As of 12/7/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
685,132 shs
Average Volume
766,374 shs
Market Capitalization
$722.86 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ZGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for Zogenix and its competitors with MarketBeat's FREE daily newsletter.

Zogenix logo

About Zogenix

Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.


Zogenix (NASDAQ:ZGNX) Shares Gap Up to $11.25
December 1, 2021 |  americanbankingnews.com
Zogenix, Inc. (NASDAQ:ZGNX) Director Sells $62,174.60 in Stock
November 30, 2021 |  americanbankingnews.com
Zogenix (NASDAQ:ZGNX) Reaches New 52-Week Low at $11.38
November 29, 2021 |  americanbankingnews.com
Zogenix (NASDAQ:ZGNX) Reaches New 52-Week Low at $13.01
November 22, 2021 |  americanbankingnews.com
Traders Purchase Large Volume of Put Options on Zogenix (NASDAQ:ZGNX)
November 17, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$13.64 million
Book Value
$4.01 per share


Net Income
$-209.38 million
Net Margins
Pretax Margin




Free Float
Market Cap
$722.86 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.92 out of 5 stars

Medical Sector

720th out of 1,394 stocks

Pharmaceutical Preparations Industry

341st out of 673 stocks

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Zogenix (NASDAQ:ZGNX) Frequently Asked Questions

Is Zogenix a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zogenix stock.
View analyst ratings for Zogenix
or view top-rated stocks.

How has Zogenix's stock price been impacted by Coronavirus?

Zogenix's stock was trading at $22.69 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ZGNX shares have decreased by 43.1% and is now trading at $12.91.
View which stocks have been most impacted by COVID-19

When is Zogenix's next earnings date?

Zogenix is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Zogenix

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) posted its earnings results on Thursday, November, 4th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.96) by $0.08. The company earned $22.61 million during the quarter, compared to analysts' expectations of $22.71 million. Zogenix had a negative trailing twelve-month return on equity of 80.20% and a negative net margin of 381.69%. The company's quarterly revenue was up 690.6% on a year-over-year basis. During the same period in the previous year, the business posted ($1.02) earnings per share.
View Zogenix's earnings history

What price target have analysts set for ZGNX?

7 Wall Street analysts have issued 12 month price targets for Zogenix's shares. Their forecasts range from $17.67 to $62.00. On average, they expect Zogenix's share price to reach $33.67 in the next year. This suggests a possible upside of 160.8% from the stock's current price.
View analysts' price targets for Zogenix
or view top-rated stocks among Wall Street analysts.

Who are Zogenix's key executives?

Zogenix's management team includes the following people:
  • Stephen James Farr, President, Chief Executive Officer & Director
  • Ashish M. Sagrolikar, Chief Operating Officer & Executive Vice President
  • Michael Patrick Smith, Chief Financial Officer, Treasurer & Executive VP
  • Bradley S. Galer, Chief Medical Officer & Executive Vice President
  • Steven A. Johnson, Vice President, Legal Council & Compliance Office

What is Stephen Farr, Ph.D.'s approval rating as Zogenix's CEO?

7 employees have rated Zogenix CEO Stephen Farr, Ph.D. on Glassdoor.com. Stephen Farr, Ph.D. has an approval rating of 85% among Zogenix's employees.

What other stocks do shareholders of Zogenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zogenix investors own include GW Pharmaceuticals (GWPH), Gilead Sciences (GILD), Vanda Pharmaceuticals (VNDA), AbbVie (ABBV), QUALCOMM (QCOM), Advanced Micro Devices (AMD), (CGC), Sorrento Therapeutics (SRNE), Southwest Airlines (LUV) and Micron Technology (MU).

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

Who are Zogenix's major shareholders?

Zogenix's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.41%), Morgan Stanley (6.39%), RA Capital Management L.P. (5.95%), Farallon Capital Management LLC (4.94%), Artisan Partners Limited Partnership (4.42%) and Marshall Wace LLP (3.66%). Company insiders that own Zogenix stock include Ashish M Sagrolikar, Cam L Garner, James B Breitmeyer, Mark C Wiggins, Michael P Smith, Renee P Tannenbaum and Stephen J Farr.
View institutional ownership trends for Zogenix

Which major investors are selling Zogenix stock?

ZGNX stock was sold by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Granite Point Capital Management L.P., Morgan Stanley, Bank of New York Mellon Corp, Millennium Management LLC, ING Groep NV, Marshall Wace LLP, and Dimensional Fund Advisors LP.
View insider buying and selling activity for Zogenix
or view top insider-selling stocks.

Which major investors are buying Zogenix stock?

ZGNX stock was bought by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Farallon Capital Management LLC, Jane Street Group LLC, Janus Henderson Group PLC, Rice Hall James & Associates LLC, Eversept Partners LP, HealthInvest Partners AB, and Prosight Management LP. Company insiders that have bought Zogenix stock in the last two years include Ashish M Sagrolikar, Cam L Garner, Mark C Wiggins, and Renee P Tannenbaum.
View insider buying and selling activity for Zogenix
or or view top insider-buying stocks.

How do I buy shares of Zogenix?

Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zogenix's stock price today?

One share of ZGNX stock can currently be purchased for approximately $12.91.

How much money does Zogenix make?

Zogenix has a market capitalization of $722.86 million and generates $13.64 million in revenue each year. The company earns $-209.38 million in net income (profit) each year or ($4.35) on an earnings per share basis.

How many employees does Zogenix have?

Zogenix employs 218 workers across the globe.

What is Zogenix's official website?

The official website for Zogenix is www.zogenix.com.

Where are Zogenix's headquarters?

How can I contact Zogenix?

Zogenix's mailing address is 5959 Horton Street Suite 500, EMERYVILLE CA, 94608. The company can be reached via phone at (510) 550-8300, via email at [email protected], or via fax at 858-259-1166.

This page was last updated on 12/8/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.